Eisai China Inc. is a pharmaceutical company wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. Eisai has been smoothly developing its business in China since the early 1990s, Eisai China, Inc. currently promotes more than 10 pharmaceutical brands in China, specializing in the Central Nervous System, Digestive System, Endocrine and Orthopedic areas.
|Chapter 1||Shenyang Eisai, Business Initial（1991-1995）|
|1991||Shenyang Eisai Pharmaceutical Co., Ltd. was established.|
|1993||Production of NEQ tablet officially started in China.|
|Chapter 2||Suzhou Eisai, Product Localization（1996-2001）|
|1996||Eisai(Suzhou)Pharmaceutical Co., Ltd. was established.|
|1997||Mecobalamin Injection and Neuqinon were launched in China.|
|1998||Eisai(Suzhou)Pharmaceutical Co., Ltd. obtained GMP certification.|
|1999||Production of Eisai Suzhou officially started in May, Merislon and Myonal were launched in China.|
|Chapter 3||Eisai China Inc., Product Line Enrichment（2002-2014）|
|2002||Company Name was officially changed to Eisai China Inc.|
|2003-2006||Mecobalamin sugar-coated tablet, Aricept, Fareston, Pariet, Selbex, and Stronger Neo-Minophagen C were launched in China.|
|2009-2014||Eisai China Inc. established 9 branches in Beijing, Guangzhou, Chengdu, Xi’an, Shenyang, Hangzhou, Qingdao, Tianjin, and Fuzhou.|
|2010||Eisai (Suzhou) Trading Co., Ltd. was established.|
|2014||Mecobalamin film-coated tablet was launched in China.|
|Chapter 4||Eisai China Holdings, Enterprise Group Development（2014-now）|
|2014||Eisai China Holdings Ltd. was established and China Region was set up.
Eisai China Inc. completed construction of new parenteral facility.
|2015||Eisai Liaoning Pharmaceutical Co., Ltd. was established; Eisai China entered the generic drug market in China.|
|2016||E-WAY 2025 , a 10-year mid -tern plan, was official launched.|
|2017||Eisai China Inc. completed construction of oral solid dose production facility.|
|2017||Aricept was approved for SAD indication in China; Stalevo and Comtan were introduced to China.|
|2018||Cidine and Lenvima were launched in China.|